Experimental Hepatitis B Treatment

In Comparison to Adefovir, the Efficacy of Tenofovir Seems Unchanged by the Presence of Lamivudine-resistant HBV - 11/23/05

Experimental HBV Drug Pradefovir: Safety, Tolerability, Antiviral Activity, and Pharmacokinetics - 11/21/05

First Line Combination Therapy for Chronic Hepatitis B in HBV-HIV Coinfected Patients with Tenofovir Plus Lamivudine versus Sequential Treatment with Tenofovir Monotherapy after Lamivudine Failure - 11/21/05

Antiviral Response and Resistance Surveillance for HBeAg-negative Patients in a Study Evaluating Emtricitabine Plus Clevudine versus Emtricitabine Monotherapy - 11/21/05

Maximal Early HBV Suppression is Predictive of Optimal Virologic and Clinical Efficacy in Nucleoside-Treated Hepatitis B Patients: The GLOBE Study - 11/18/05

Histologic Improvement in Patients with Chronic Hepatitis B after Treatment with Peginterferon alfa-2a (Pegasys) Monotherapy - 11/18/05

Tenofovir Appears Highly Effective as Salvage Therapy for HBV Patients with Suboptimal Response to Adefovir - 11/16/05

Treatment with Tenofovir Results in a Rapid Decrease of HBV-DNA Viral Load in Patients with Resistance or Sub-optimal Response to Adefovir - 11/16/05

<--- Return to the 56th AASLD Main Page